336 results about "Treatment targets" patented technology

The invention relates to the technical field of medicines, in particular to a construction method and application of a photothermal conversion platform for treating osteoarthritis by regulating synovial macrophage polarization. According to the present invention, the M2 membrane-structured black phosphorus selenium carbon body (M2-BPSeC) photo-thermal nano-platform is innovatively provided, the triple functions of bionic targeting delivery, precise thermal control intervention and immune microenvironment remodeling are integrated, and the excellent synergistic treatment effect is represented in the in-vitro cell model and the OA animal model. The technology breaks through the technical bottleneck that traditional treatment is insufficient in targeting and single in intervention dimension, precise functional coupling of the physical thermal effect and immunoregulation is achieved for the first time, and a brand new strategy of targeting-temperature control-immunity integration is provided for osteoarthritis treatment. The efficient and controllable preparation process and the remarkable multi-dimensional treatment effect open up a new path for cartilage regeneration and immune balance regulation and control.

The invention discloses a net ultrafiltration rate intelligent regulation and control device and method for CRRT treatment, and relates to the technical field of medical equipment control, and the device comprises a sensor module, a data processing module and a regulation and control module; the sensor module is used for acquiring CRRT treatment associated data of a preset patient; the data processing module is used for predicting a blood volume tolerance curve of a preset patient by utilizing an artificial intelligence technology according to historical CRRT treatment data and CRRT treatment associated data of the preset patient, and generating a net ultrafiltration rate time sequence scheme according to the predicted blood volume tolerance curve and a preset treatment target of the preset patient; and the regulation and control module is used for automatically regulating the rotating speed of a blood pump and the rotating speed of a displacement liquid pump which are used for performing CRRT treatment on the preset patient according to the net ultrafiltration rate time sequence scheme, and regulating the dehydration rate of the preset patient. According to the invention, a more accurate intelligent regulation and control mode can be provided for CRRT treatment.

The invention relates to the field of biological medicine, in particular to application of a reagent for measuring or regulating the expression level of HIF-1alpha in preparation of a kit for diagnosing or gout, the kit containing the reagent and a gout prediction device. The HIF-1alpha is applied as a gout diagnosis target and a treatment target for the first time, the polarization degree of Th17 cells in an inflammatory microenvironment of a gout patient can be specifically reflected, early dynamic monitoring of gout related inflammatory activities is achieved, polarization of Th17 cells and expression of related proinflammatory factors are inhibited in a targeted mode, and a new strategy is provided for prediction, diagnosis and treatment of gout.

The invention belongs to the field of biological medicine, and discloses a blood marker for identifying epilepsy convulsion and application thereof. The inventor finds that the LRG1 is obviously increased during epileptic convulsion, which indicates that the increase of the blood LRG1 is a blood marker during the acute attack stage of epileptic convulsion. The invention proposes and verifies that the LRG1 is the peripheral blood marker in the acute attack stage of epilepsy convulsion for the first time, and can be used as a clinical auxiliary diagnosis and treatment target.

The invention provides an infrared physiotherapy cabin system and method based on animal and environment cooperative regulation and control, and relates to the field of animal physiotherapy and intelligent monitoring control. Comprising an animal state and cabin environment monitoring module, an infrared physiotherapy and cabin environment regulation and control module, an animal health assessment and curative effect assessment module, a personalized treatment and intelligent decision module and a man-machine interaction and safety supervision module. A credibility result is formed through multi-modal data synchronous alignment and data quality evaluation, health state characterization is constructed under credibility gating, a risk level is output, and infrared physiotherapy control parameters and cabin environment regulation and control parameters are generated through cooperative control under the constraint of a stage control boundary and a treatment target and are issued and executed. Continuously adjustable parameters are subjected to online fine adjustment in the physiotherapy process, and rollback and interlocking protection is executed when the risk is increased or the credibility is reduced; after the period is finished, the curative effect is evaluated, data recording and tracing archiving are completed, and collaborative closed-loop infrared physiotherapy regulation and control of the animal state and the in-cabin environment are achieved.

The invention relates to the crossing field of computer technology and edge calculation, and discloses a blood purification equipment real-time control method based on edge calculation. According to the method, multi-modal real-time physiological parameters, historical dialysis data and a current treatment target are fused through a local edge calculation unit, an individualized body fluid dynamic response prediction model is constructed, and an ultrafiltration rate instruction is optimized and generated within a millisecond level; the system comprises a multi-mode sensor array, a historical data storage module, a task planning interface, an edge computing unit and an ultrafiltration pump controller. According to the application, the hemodynamic state is accurately maintained, the risk of hypotension is remarkably reduced, and the treatment safety and individualization level are improved.

The invention relates to the technical field of biological medicines, and provides application of NR1D1 in treating sicca syndrome, related medicines and the like. The scheme of the invention discovers and proves that the NR1D1 gene participates in the sicca syndrome pathogenesis process, can significantly influence the function of submaxillary gland cells, and is an effective sicca syndrome immune inflammation regulation diagnosis and treatment target.

The invention relates to the technical field of biomedicine, in particular to a method for regulating and controlling the liquid-liquid phase separation capacity and function of DUX4 and application of the method, and the liquid-liquid phase separation capacity and function of the DUX4 are regulated and controlled by mutating an internal disordered region of the DUX4. The invention finds that the mutation has a remarkable inhibition effect on expression of DUX4 activated totipotent genes and FSHD related genes; according to the method, an intracellular liquid-liquid phase separation model is constructed through intracellular overexpression of DUX4; a research basis and a model are provided for subsequent LLPS research of DUX4, and thinking and mechanism explanation are provided for research of DUX4-mediated facial shoulder brachial muscular dystrophy (FSHD) and development of treatment targets.

The invention provides a biomarker for cervical lesion caused by low folic acid mediated HPV infection and application of the biomarker, the biomarker is IGF2BP3 and miR-27a, and the IGF2BP3 and the miR-27a can be used as a therapeutic target and a research tool for cervical lesion caused by low folic acid mediated HPV infection. The small nucleic acid targeting IGF2BP3 and miR-27a is delivered through the folic acid modified exosome in cervical lesion treatment, and the delivery efficiency and the treatment effect are remarkably improved.

The invention discloses application of miR-101-3p in preparation of a medicine for treating myocardial fibrosis, and relates to the technical field of medicines. According to the invention, the influence of the miR-101-3p / RAC1 / PAK1 pathway on endothelial cells EndMT is verified by adopting human umbilical vein endothelial cells and utilizing molecular and cell biology means; and constructing an HFrMF mouse model, and verifying the feasibility of intervening the signal channel to alleviate MF. And a thought is provided for clarifying the pathological mechanism of heart failure and exploring a new treatment target.

The invention discloses TCN1 (Trancobalamin 1, cobalamin 1) and application of an inhibitor of the TCN1 in preparation of products for diagnosing and treating diseases of an autoimmune system. According to the invention, expression in psoriasis tissues is up-regulated and promoter DNA methylation is down-regulated into genes to screen TCN1 genes, an over-expression TCN1 HaCaT cell line is constructed, and it is verified that the over-expression TCN1 HaCaT cell line participates in keratinocyte proliferation and IL-17 activation as an autoantigen, can be used as a diagnostic marker and a therapeutic target of autoimmune skin diseases such as psoriasis and the like, and has broad application prospects. And a new direction is provided for mechanism research and treatment of autoimmune skin diseases such as psoriasis.

A system includes at least one processor configured to execute computer executable instructions to cause the system to: generate or obtain a first radiation treatment plan for a treatment target in a patient, the first radiation treatment plan prescribing beam characteristics for a plurality of beamlets or spots in the treatment target, the beam characteristics including a monitor unit value associated with each of the plurality of beamlets or spots in at least a first field; and display, via a graphical user interface, at least one representation of a first distribution of monitor units for the first radiation treatment plan, the at least one representation of the first distribution of monitor units indicating, for each respective monitor unit value, a number of beamlets or spots in at least the first field having the respective monitor unit value.

The invention belongs to the field of biomedicine, and provides application of LDHA as a treatment target of aging-related osteoarthritis. In-vitro cell experiments and animal in-vivo experiments prove that the LDHA inhibitor can inhibit OA progress caused by aging, and targeted inhibition of LDHA in synovial fibroblasts can provide a brand-new treatment strategy for treatment of aging-related osteoarthritis.

The invention relates to the technical field of brain disease target positioning, in particular to a brain disease target positioning system and method based on functional magnetic resonance imaging. The method comprises the following steps: calculating a whole brain function connection map of an individual patient based on 4D rs-fMRI data, calculating a Z score of each voxel function connection strength in the whole brain function connection map of the individual patient, and screening abnormal voxels based on a preset threshold value; aggregating the abnormal voxels through a clustering algorithm so as to determine a cluster; the therapeutic effect scores of the multiple clusters can be predicted through the machine learning model, the clusters and the candidate therapeutic targets can be screened based on the therapeutic effect scores, the positions of the candidate targets can be accurately determined, and multiple selections of the candidate targets can be provided; the target spot is converted into an accurate target spot suitable for an individual through a nonlinear registration algorithm; and determining a target positioning state according to the deviation between the accurate target and the actual treatment target, and adjusting corresponding parameters based on the target positioning state. The invention provides a plurality of targets and effectively determines the positions of the targets.

The present invention discloses a beta-ray therapy device and a method for using the same, which belongs to the field of nuclear medicine external radiation therapy. The device includes a therapy device body and a conformal structure. The therapy device body includes a beta-ray source and a beta-ray shielding structure. The beta-ray shielding structure has a mounting cavity and a window communicating with the mounting cavity. The beta-ray source is installed in the mounting cavity. The conformal structure includes a conformal frame and a plurality of conformal pieces. A transmission area is opened in the center of the conformal frame. The conformal pieces are installed on the conformal frame and are movable toward or away from the transmission area. By adjusting the position of the conformal piece, a conformal area surrounding a treatment target area is formed within the transmission area. The beta-ray source transmits beta-rays through the window toward the conformal area. The present invention can form conformal areas of different shapes according to different shapes of treatment target areas. Then, the beta-rays emitted by the beta-ray source transmit through the conformal area to irradiate the treatment target area, thereby allowing the same therapy device to treat treatment target areas of different shapes, thereby achieving versatility and adjustability.

The application provides GPC1 in preventing and / or treating 131 The application of inhaled internal radiation in causing thyroid cancer belongs to the technical field of biological medicine. The application takes GPC1 as 131 A treatment target of inhaled internal radiation in causing thyroid cancer, and finds that high expression of GPC1 can promote the proliferation, migration and invasion of thyroid cancer cells, and low GPC1 inhibits the occurrence and development of thyroid cancer. Therefore, the application provides application of a reagent for inhibiting, knocking down or knocking out GPC1 in preparation of a drug for preventing and / or treating thyroid cancer. The application also provides that deletion of GPC1 can effectively alleviate 131 The phenotypes of thyroid cancer caused by inhaled internal radiation, and GPC1 is an effective target for preventing and treating 131 Thyroid cancer caused by inhaled internal radiation.

The invention relates to the technical field of medical treatment, and discloses a lung cancer personalized treatment scheme recommendation method and system and a storage medium. The method comprises the following steps: acquiring clinical and molecular indexes of a patient, and constructing a simplified feature set; distributing weights for treatment targets according to the simplified feature set, constructing and optimizing a scheme evaluation matrix, and generating a preliminary scheme sorting list; through threshold screening and patient feature matching degree verification, a verified scheme set is obtained; the schemes are classified based on gene mutation and driver gene features, and classified optimization scheme subsets are obtained; constructing an interaction model to analyze interaction influence of toxic and side effects and life quality on curative effects, and dynamically adjusting scheme scores; and if the score is lower than a threshold value, triggering iterative optimization, obtaining a scheme list after iteration, and further determining an optimal treatment scheme according to treatment collaboration and target balance. According to the method, intelligent and closed-loop optimization from multi-source data to personalized treatment decision is realized, and the personalization and accuracy of a treatment scheme are improved.

The invention provides a medicine for treating sepsis-related acute kidney injury, belongs to the technical field of small molecule medicines, and particularly provides a medicine for treating sepsis-related acute kidney injury, which comprises a NOX4 inhibitor. And the NOX4 inhibitor comprises GLX351322 (GLX351322). According to the application, it is clear that the NOX4 level in serum of an S-AKI patient is remarkably increased and is in positive correlation with kidney injury, it is proved that GLX351322 has remarkable treatment and renal function protection effects on acute kidney injury caused by bacterial infection or acute kidney injury caused by lipopolysaccharide exposure, and a new treatment target and a new drug development direction are provided for sepsis-related acute kidney injury.

The invention belongs to the technical field of biomedicine, and particularly relates to a diagnostic marker for lung transplantation rejection and application of the diagnostic marker. The invention discloses one or more of OIT3, CAMP, USP4, IPO9 and PON1 as markers for diagnosis, monitoring, curative effect evaluation or prognosis evaluation of the lung transplantation rejection for the first time, and diagnosis, monitoring, curative effect evaluation or prognosis evaluation of the lung transplantation rejection can be realized by detecting the content, expression quantity and / or activity of the markers. The invention discloses that the OIT3 can be used as a diagnosis and treatment target of the lung transplantation rejection for the first time, and diagnosis, monitoring, curative effect evaluation or prognosis evaluation of the lung transplantation rejection can be realized by detecting the content, expression quantity and / or activity of the OIT3; the lung transplantation rejection reaction can be prevented and / or treated through the OIT inhibitor.

The invention discloses a traditional Chinese and western medicine cooperative emotion nursing management system and a physiotherapy robot applying the same, and aims to solve the technical problems in the aspects of traditional Chinese and western medicine theory deep cooperation and dynamic personalized nursing in the prior art. The system is realized through the following steps: collecting physiological, behavior, traditional Chinese medicine and other multi-modal data of a user, and constructing a unified traditional Chinese and western medicine cooperative emotional state vector; reasoning by using a traditional Chinese and western medicine fusion knowledge graph to generate an interpretable traditional Chinese medicine macroscopic treatment target; a double-layer hierarchical reinforcement learning model is adopted for decision making, a macroscopic intervention combination is generated through a high-layer strategy, and an accurate robot control instruction containing emotional tactile parameters is generated through a low-layer strategy; and finally, driving the physiotherapy robot to execute the instruction, and continuously optimizing the strategy through closed-loop feedback. According to the method, the artificial intelligence decision theory and the traditional Chinese medicine syndrome differentiation treatment thought are combined, and an automatic and emotional traditional Chinese and western medicine cooperative nursing solution is provided for mood-related functional disorders.

The present disclosure provides a radiotherapy plan generation method, comprising: obtaining object information of a target object, the object information comprising at least medical image information and a treatment target of the target object; calculating a field intensity distribution according to the object information, the field intensity distribution comprising a plurality of dose grids and beam information of a corresponding beam of each dose grid; selecting a target dose grid from each dose grid based on a difference between an actual dose of each dose grid and a target dose; constructing an inverse optimization problem according to each target dose grid; and solving the inverse optimization problem to generate a radiotherapy plan.

The invention discloses application of a lactic acid modified gene ENO1 inhibitor in preparation of a medicine for treating nasopharynx cancer, and relates to the technical field of biological medicines. A head and neck squamous cell carcinoma prognosis model containing seven lactylation related genes is constructed by analyzing a TCGA database, the model can effectively distinguish patient risks, the total lifetime of a high-risk group is remarkably shortened, and a risk score is an independent prognosis factor; the functions of the key gene ENO1 are deeply studied through in-vitro experiments, and experimental results show that silencing of the ENO1 gene in nasopharynx cancer 5-8F cells causes up-regulation of cell pan-lactylation level, up-regulation of MMP2 expression and down-regulation of E-cadherin expression, and migration and invasion ability of tumor cells is significantly enhanced. The prognosis model provided by the invention has an important clinical prediction value, inhibition of ENO1 can promote tumor progression through abnormal lactylation, and a new thought is provided for taking ENO1 as a treatment target.

The application relates to the fields of medical diagnosis and gene drugs, and particularly relates to application of long-chain non-coding RNA in preparation of a heart insufficiency diagnosis reagent or kit. The application also provides application of the long-chain non-coding RNA in preparation of a heart insufficiency treatment drug. The application first finds that LOC107984012 is long-chain non-coding RNA which is highly expressed in a failing heart, and provides a new diagnosis marker and treatment target for heart insufficiency.

The application discloses a polypeptide GRN-E and application thereof in preparation of a medicine or preparation for perimenopausal emotional disorder. It is found for the first time that a GRN-E fragment (a C-terminal domain of PGRN, an amino acid sequence is SEQ ID NO. 1 in a sequence listing) can pass through a blood-brain barrier and has a unique effect in relieving perimenopausal anxiety and depression. As a key functional fragment, the GRN-E has a more concentrated effect on a central nervous system and can effectively avoid off-target effects of a full-length protein. The polypeptide GRN-E of the application can be applied to preparation of a medicine or preparation for perimenopausal emotional disorder as an innovative treatment target and a novel biological preparation and has a high clinical conversion value.

The invention discloses application of CD300LF in head and neck squamous cell carcinoma prognosis products, and belongs to the technical field of biomedicine. It is found that CD300LF is highly expressed in head and neck squamous cell carcinoma tumor tissues and is mainly enriched on tumor-related macrophages, expression up-regulation of CD300LF is remarkably positively correlated with tumor metastasis and pathological staging of a patient, and correspondingly, prognosis of the patient is poor. Therefore, the CD300LF can be used as a prognosis diagnosis marker and a treatment target of the head and neck squamous cell carcinoma, and can be widely applied to preparation of diagnosis kits and prevention and treatment medicines of the head and neck squamous cell carcinoma.

The invention discloses application of ACSS2 as an action target in screening or preparing a medicine for preventing or treating virus-induced vascular remodeling diseases, and belongs to the field of biological medicine. It is found that by inhibiting ACSS2 gene expression or protein activity, Zika virus induced vascular smooth muscle cell phenotypic transformation can be remarkably reversed, and occurrence and development of angiotensin II / aminopropionitrile induced aortic aneurysm / dissection are relieved. The invention provides a siRNA sequence (SEQ ID NO.1-2) specifically targeting ACSS2 and a pharmaceutical composition containing the siRNA, and provides a novel treatment target and a precise intervention tool for virus-related vascular remodeling diseases.

The invention relates to the technical field of biology, in particular to application of a prostate intermediate state cell and an inhibitor of the prostate intermediate state cell, and discloses application of the prostate intermediate state cell and an organ or tissue comprising the prostate intermediate state cell as a target in screening of drugs for treating prostatitis or prostatic hyperplasia. The prostate intermediate state cell inhibitor is applied to preparation of a medicine for treating prostatitis or benign prostatic hyperplasia; the inhibitor of the prostate intermediate state cells comprises one or more of a GRN signal channel inhibitor and a Sema4 signal channel agonist. The application provides a new therapeutic target for treatment of prostatitis or benign prostatic hyperplasia and drug screening, and provides a potential strategy for clinical treatment of prostatitis and benign prostatic hyperplasia.

The application provides a Circ-SLC25A24 which is highly expressed in glioma and has coding function and a Circ-SLC25A24-19KD coded by the Circ-SLC25A24. By inhibiting the Circ-SLC25A24 nucleotide through siRNA, shRNA or AS O, the proliferation, migration, invasion and the like of glioma cells can be significantly inhibited. The Circ-SLC25A24 or the Circ-SLC25A24-19KD can be used as a glioma diagnosis marker and a treatment target. The Circ-SLC25A24-19KD amino acid sequence coded by the ORF of the Circ-SLC25A24 across a splicing site has specificity and can be used as a specific target of a molecular targeted drug, provides a new idea for the research and development of a drug for treating glioma, and has important clinical medication value.

The invention provides an EP300 detection preparation and application of EP300 in a product for treating rheumatoid arthritis, and relates to the technical field of biological medicines. The rheumatoid arthritis symptom is relieved by inhibiting EP300 gene expression, after EP300 is knocked down in human THP-1-derived macrophages, H3K18 lactylation expression is reduced, and after EP300 is knocked down in human THP-1-derived macrophages, EP300 and human synovial cells are co-cultured, so that the human THP-1-derived macrophages are subjected to H3K18 lactylation expression is reduced, the human THP-1-derived macrophages are subjected to H3K18 lactylation expression is reduced, and the human THP-1-derived macrophages are obtained. Through the crosstalk effect between human THP-1-derived macrophages and human synovial cells, the expression of inflammatory markers MMP3 and Fibronectin in the synovial cells can be remarkably inhibited, compared with a model group, the proliferation capacity of the synovial cells is weakened, a potential treatment target is provided for treating rheumatoid arthritis, and the application has the advantages that the application is easy to popularize and use, and the application has a wide application prospect. The pathogenesis of rheumatoid arthritis is perfected, and hope is brought to research and development of novel biomarkers for early diagnosis, targeted therapy and prognosis evaluation of rheumatoid arthritis.

Treatment instrument (12) comprising: a first treatment body (344) having a treatment surface (352) to be used as a high-frequency electrode and configured to receive, together or separately, a high-frequency energy and another energy that differs from the high-frequency energy input into the treatment surface (352); and a second treatment body (402) configured to treat a treatment target in conjunction with the treatment surface (352), wherein the second treatment body (402) comprises: a contact section (462) extending along a longitudinal axis (L2) and possessing an electrically insulating property; and a first surface (452) which is used as the first high-frequency electrode, wherein: the first surface (452) borders the contact section (462) in a first lateral direction (W1) perpendicular to the longitudinal axis (L2), the contact section (462) faces the treatment surface (352) of the first treatment body (344), wherein the contact section (462) is configured to move between an open state in which the contact section (462) is separated from the treatment surface (352) along opening and closing directions, and a closed state in which the contact section (462) is closed relative to the treatment surface (352), and the contact section (462) is configured to be brought into contact with the treatment surface (352) in the closed state, and the first surface (452) is separated from the treatment surface (352) in both the open and closed states and comprises a first near edge (482a) of the first surface (452), wherein the first near edge (482a) is located near the contact section (462); and a first outer edge (482b) which is spaced from the contact section (462) from the longitudinal axis (L2) in the direction of a first side surface (384a) of a treatment section (326) in the first width direction (W1), and Assuming that a virtual plane (VP) is defined such that in the closed state it is perpendicular to the opening and closing directions and passes through the first near edge (482a) of the first surface (452), at a distance between the virtual plane (VP) and the first surface (452) a distance between the first outer edge (482b) and the virtual plane (VP) is greater than a distance between the first near edge (482a) and the virtual plane (VP).